Hebei Changshan Biochem Pharma Net Asset Momentum
Hebei Changshan Biochem Pharma net asset momentum. Hebei Changshan Biochem Pharma (300255) recorded a net asset momentum of -14.7% as of December 2024, with net assets of CN¥1.54 Billion CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore 300255 capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of Hebei Changshan Biochem Pharma (2008–2024)
Net asset momentum of Hebei Changshan Biochem Pharma from 2008 to 2024. This chart tracks Hebei Changshan Biochem Pharma's year-over-year net asset growth across 17 annual reporting periods from 2008 to 2024. The most recent momentum reading is -14.7%, with net assets of CN¥1.54 Billion CNY as of December 2024. See Hebei Changshan Biochem Pharma (300255) net assets for net asset value and shareholders' equity analysis.
Hebei Changshan Biochem Pharma Net Asset Momentum by Year (2008–2024)
Hebei Changshan Biochem Pharma net asset momentum by year from 2008 to 2024. The table below shows the complete annual net asset history for Hebei Changshan Biochem Pharma from 2008 to 2024, covering 17 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see 300255 market cap.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2024 | CN¥1.54 Billion | CN¥4.52 Billion | CN¥2.99 Billion | ▼ -14.7% |
| 2023 | CN¥1.80 Billion | CN¥4.60 Billion | CN¥2.80 Billion | ▼ -41.1% |
| 2022 | CN¥3.05 Billion | CN¥6.04 Billion | CN¥2.98 Billion | ▼ -0.6% |
| 2021 | CN¥3.07 Billion | CN¥5.19 Billion | CN¥2.12 Billion | ▲ +7.7% |
| 2020 | CN¥2.85 Billion | CN¥4.57 Billion | CN¥1.72 Billion | ▲ +4.8% |
| 2019 | CN¥2.72 Billion | CN¥3.94 Billion | CN¥1.22 Billion | ▲ +7.9% |
| 2018 | CN¥2.52 Billion | CN¥3.84 Billion | CN¥1.32 Billion | ▲ +3.6% |
| 2017 | CN¥2.44 Billion | CN¥3.53 Billion | CN¥1.09 Billion | ▲ +6.4% |
| 2016 | CN¥2.29 Billion | CN¥3.13 Billion | CN¥842.59 Million | ▲ +45.7% |
| 2015 | CN¥1.57 Billion | CN¥2.33 Billion | CN¥757.07 Million | ▲ +10.1% |
| 2014 | CN¥1.43 Billion | CN¥2.04 Billion | CN¥617.87 Million | ▲ +11.0% |
| 2013 | CN¥1.29 Billion | CN¥1.65 Billion | CN¥359.78 Million | ▲ +14.2% |
| 2012 | CN¥1.13 Billion | CN¥1.42 Billion | CN¥292.77 Million | ▲ +14.0% |
| 2011 | CN¥987.45 Million | CN¥1.19 Billion | CN¥198.78 Million | ▲ +350.1% |
| 2010 | CN¥219.39 Million | CN¥430.64 Million | CN¥211.25 Million | ▲ +37.8% |
| 2009 | CN¥159.19 Million | CN¥266.35 Million | CN¥107.15 Million | ▲ +70.4% |
| 2008 | CN¥93.43 Million | CN¥196.59 Million | CN¥103.16 Million | — |